Tomasz H.
- Country
- Poland
- Department
- NA
Research Overview
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
- Evaluation of Ravulizumab Efficacy and Safety in Adult Patients with Immunoglobulin A Nephropathy: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Obinutuzumab Versus Tacrolimus in Primary Membranous Nephropathy: A Phase III Randomized Controlled Trial
Data & Insights
Has run more than one trial at 37 of 171 partner sites.
Specializations
Nephrology Focus
This investigator specializes in the study of renal disorders, with particular emphasis on immune-mediated kidney diseases. Their research encompasses innovative therapeutic approaches for treating various forms of glomerulonephritis.
- IgA Nephropathy (IgAN)
- Primary Membranous Nephropathy
The investigator explores novel therapeutic pathways in autoimmune kidney diseases, focusing on antibody-mediated conditions affecting renal function.
Immunological Treatments
Their research portfolio includes investigation of targeted immunological therapies for kidney diseases, including novel monoclonal antibodies and complement-targeting agents.
- Complement Pathway Modulation
- B-Cell Targeted Therapies
- Novel Biological Agents
The investigator evaluates advanced therapeutic approaches for managing chronic kidney conditions through immune system modulation.
Clinical Outcomes
Their research interests extend to measuring and improving kidney function parameters in patients with glomerular diseases.
- Proteinuria Reduction
- Renal Function Preservation
- Disease Remission Strategies
The investigator focuses on evaluating treatment efficacy through comprehensive assessment of kidney disease markers and patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.